The radio pharmacy closely interacts with the pre-clinical imaging division for the development and validation of novel radiotracers in the field of oncology and neurosciences.
Currently, there are research programs on pre-targeting strategies (for biologicals) as well as strategic basic research on the use of polymers to increase labeling efficiency.
So far, pre-clinical proof-of-concept has been achieved in two programs focusing on i) monitoring tumor-associated protease activity and ii) radiotracers for visualizing cell death as part of tumor phenotyping. At his moment we are exploring (funding) opportunities to validate these promising results in clinical trials.
A last research track involves the development of tracers to visualize phosphodiesterase (PDE) activity and other brain targets.